FOLFOX-4 vs. doxorubicin for hepatocellular carcinoma: could a negative result be accepted as positive?

Affiliations

¹ BCLC Group, Liver Unit, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERehd, Spain.
² BCLC Group, Liver Unit, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERehd, Spain. Electronic address: jbruix@clinic.ub.es.

Free article

Comment

Alexandre Liccioni et al. J Hepatol. 2014 Jul.

Free article

. 2014 Jul;61(1):164-5.

doi: 10.1016/j.jhep.2014.03.024. Epub 2014 Mar 27.

¹ BCLC Group, Liver Unit, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERehd, Spain.
² BCLC Group, Liver Unit, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERehd, Spain. Electronic address: jbruix@clinic.ub.es.

No abstract available

Keywords: BCLC; HCC; Treatment.

Comment on

Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
Qin S, Bai Y, Lim HY, Thongprasert S, Chao Y, Fan J, Yang TS, Bhudhisawasdi V, Kang WK, Zhou Y, Lee JH, Sun Y. Qin S, et al. J Clin Oncol. 2013 Oct 1;31(28):3501-8. doi: 10.1200/JCO.2012.44.5643. Epub 2013 Aug 26. J Clin Oncol. 2013. PMID: 23980077 Clinical Trial.